XSTOASAP
Market cap57kUSD
Oct 01, Last price
0.03SEK
Name
Asarina Pharma AB (publ)
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.14%
Rev. gr., 5y
%
Revenues
0k
Net income
-13m
L-3.43%
CFO
-11m
L+20.96%
Earnings
Feb 25, 2025
Profile
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 6,917 | 10,788 | 33,218 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (6,917) | (10,788) | (33,218) | ||||
NOPBT Margin | |||||||
Operating Taxes | 1,750 | (1,545) | (6,639) | ||||
Tax Rate | |||||||
NOPAT | (8,667) | (9,243) | (26,579) | ||||
Net income | (12,828) -3.43% | (13,283) -58.04% | (31,658) -57.93% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 5,844 | 371 | |||||
BB yield | -33.48% | -1.02% | |||||
| Debt | |||||||
Debt current | 1,000 | 5,300 | |||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | 2 | (1,000) | |||||
Net debt | (2,162) | (13,578) | (16,416) | ||||
| Cash flow | |||||||
Cash from operating activities | (11,272) | (9,319) | (42,499) | ||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | 1,000 | 544 | 5,671 | ||||
FCF | (8,264) | (5,703) | (29,468) | ||||
| Balance | |||||||
Cash | 3,161 | 13,577 | 21,715 | ||||
Long term investments | 1,000 | 1,000 | 1,000 | ||||
Excess cash | 3,162 | 13,578 | 21,716 | ||||
Stockholders' equity | (276,033) | (263,080) | (251,669) | ||||
Invested Capital | 278,684 | 277,682 | 278,113 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 22,641 | 18,788 | 18,745 | ||||
Price | 0.88 -5.27% | 0.93 -52.06% | 1.94 -67.91% | ||||
Market cap | 19,924 14.16% | 17,454 -51.95% | 36,327 -67.84% | ||||
EV | 17,762 | 3,876 | 19,911 | ||||
EBITDA | (6,494) | (10,382) | (32,831) | ||||
EV/EBITDA | |||||||
Interest | 298 | 395 | |||||
Interest/NOPBT | |||||||